Related Experiment Video
Updated: Jun 13, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
Marion Ferreira1, Aurélie Swalduz2, Laurent Greillier3
1Department of Pneumology and Respiratory Functional Exploration, University Hospital of Tours, Tours, France.
Background:
Capmatinib is a selective MET inhibitor with demonstrated efficacy in a phase II study of non-small cell lung cancer (NSCLC) patients harboring METex14 mutations. However, the real-world outcomes of capmatinib are largely unknown. From June 2019, the French Early Access Program (EAP) provided capmatinib to METex14 NSCLC patients who were ineligible for or for whom first-line standard therapies had failed.
Methods:
IFCT-2104 CAPMATU was a multicenter study that included all METex14 NSCLC patients who received capmatinib as part of the EAP until August 2021. The primary endpoints were time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS) and objective response rate (ORR).
Results:
A total of 146 patients were included. The median age was 74.9 years, 56.6 % were never-smokers, and 32.4 % had brain metastases. The median TTF, median PFS and median OS from capmatinib initiation were 5.1 months (95 % CI 4.2-6.0), 4.8 months (95 % CI 4.0-6.0) and 10.4 months (95 % CI 8.3-13.2), respectively. Evaluation of the best response to capmatinib was available for 134 patients and resulted in an ORR of 55.3 % (95 % CI 46.8 %-63.6 %). The median PFS was 7.7 months for treatment-naïve patients and 6.0 and 4.1 months for patients who had received one or 2 + prior lines of treatment, respectively. For patients with brain metastases, the median PFS was 3.0 months. Capmatinib had a known and manageable safety profile, with grade 3 to 4 adverse events, mostly peripheral edema (8.2 %), occurring in 17.8 % of patients.
Conclusion:
In this large real-world study of METex14 NSCLC patients, the efficacy of capmatinib was confirmed, with a manageable safety profile, even in patients with brain metastases and in those who received several lines of treatment. This study reinforces the key role of capmatinib for these patients.
Insights
Capmatinib effectively treats non-small cell lung cancer (NSCLC) with METex14 mutations in real-world settings. The study confirms capmatinib
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Capmatinib is a selective MET inhibitor with proven efficacy in Phase II trials for METex14 mutated NSCLC.
- Real-world outcomes of capmatinib in this patient population remain largely uncharacterized.
- The French Early Access Program (EAP) provided capmatinib to eligible METex14 NSCLC patients.
Purpose of the Study:
- To evaluate the real-world effectiveness of capmatinib in NSCLC patients with METex14 mutations.
- To assess key clinical outcomes including time to treatment failure, progression-free survival, and overall survival.
- To determine the objective response rate and safety profile of capmatinib in a real-world setting.
Main Methods:
- The IFCT-2104 CAPMATU study was a multicenter trial involving METex14 NSCLC patients treated with capmatinib via the EAP.
- Data were collected from June 2019 to August 2021.
- Primary endpoints included time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).
Main Results:
- 146 patients were included, with a median age of 74.9 years; 56.6% were never-smokers and 32.4% had brain metastases.
- Median TTF, PFS, and OS were 5.1, 4.8, and 10.4 months, respectively.
- Objective response rate (ORR) was 55.3%, with a median PFS of 7.7 months for treatment-naïve patients and reduced PFS in those with prior treatments or brain metastases. The safety profile was manageable, with peripheral edema being the most common grade 3-4 adverse event.
Conclusions:
- Capmatinib demonstrated confirmed efficacy in a large, real-world cohort of METex14 NSCLC patients.
- The drug exhibited a manageable safety profile, even in challenging subgroups like patients with brain metastases or those with multiple prior treatments.
- This study reinforces the significant role of capmatinib in the treatment of METex14 NSCLC.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012